ABT
Deal math, meet Wall Street math
Abbott came into April 16 with a shiny $21 billion Exact Sciences acquisition story, then promptly reminded everyone that M&A comes with a bill attached. The company trimmed its full-year adjusted EPS outlook to $5.38 to $5.58 from $5.55 to $5.80, citing 20 cents of dilution from the deal.
Why the market got a little cranky
That’s the kind of update that makes investors squint at the spreadsheet. Sure, the deal may bolster Abbott’s cancer screening ambitions down the road, but in the near term it’s pressuring profits — and the stock was down in early trading as a result.
The quarter wasn’t exactly a party either
Abbott also said first-quarter profit came in at $1.08 billion, down 18.7% from a year ago. Not disastrous, but not exactly the sort of number that screams “everything is fine, carry on.”
Big picture
This is the classic acquisition tradeoff: pay up now, hope the future pipeline makes the pain worth it later. For investors, the question is simple — can Abbott turn this expensive cancer bet into a growth engine before the dilution becomes a permanent mood?